SNY - Sanofi

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.11
+1.09 (+2.42%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close45.02
Open45.34
Bid46.14 x 1000
Ask47.47 x 1400
Day's Range45.26 - 46.11
52 Week Range40.00 - 47.47
Volume2,222,458
Avg. Volume1,465,867
Market Cap115.398B
Beta (3Y Monthly)0.48
PE Ratio (TTM)23.77
EPS (TTM)1.94
Earnings DateN/A
Forward Dividend & Yield1.74 (3.86%)
Ex-Dividend Date2019-05-07
1y Target Est52.00
  • Top Stock Reports for Chevron, HSBC & Sanofi
    Zacks

    Top Stock Reports for Chevron, HSBC & Sanofi

    Top Stock Reports for Chevron, HSBC & Sanofi

  • Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion
    Zacks

    Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion

    Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.

  • Livongo Bounces Back After Revenue Guidance Boost
    GuruFocus.com

    Livongo Bounces Back After Revenue Guidance Boost

    Analysts set average 12-month target more than 70% above current price Continue reading...

  • Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study
    Zacks

    Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study

    GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.

  • Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus
    Zacks

    Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

    Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.

  • The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
    Zacks

    The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

    The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

  • Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
    Zacks

    Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

    Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

  • Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales
    Zacks

    Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

    Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

  • Reuters

    UPDATE 1-Takeda's dengue vaccine effective overall in study but with major limitation

    Takeda Pharmaceutical Co's experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but it failed to protect against one type of the virus in people with no prior exposure to dengue. Takeda's vaccine was 80.2% effective at preventing dengue among children and teens in the year after they got the shot, according to results of a Phase III study published in the New England Journal of Medicine on Wednesday. Sanofi's Dengvaxia - the world's first dengue vaccine - had demonstrated 59.2% overall efficacy in the first year of follow-up based on combined results from two late-stage trials.

  • PR Newswire

    New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders

    *Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma *Rare Blood Disorders: New data spanning extensive portfolio demonstrates scientific ...

  • Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength
    Zacks

    Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength

    Regeneron (REGN) beats on Q3 earnings and sales on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...

  • PR Newswire

    FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

    PARIS, Nov. 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Fluzone® High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two influenza A strains and one influenza B strain. Fluzone High-Dose Quadrivalent contains an additional influenza B strain.

  • Sanofi settles 4-year legal battle over Genzyme drug for $315M
    American City Business Journals

    Sanofi settles 4-year legal battle over Genzyme drug for $315M

    Sanofi S.A. is shelling out $315 million to settle claims it bungled the launch of a multiple sclerosis drug developed by the Cambridge-based subsidiary Genzyme.

  • Eaton Vance Worldwide Health Sciences Fund Buys 2 Stocks
    GuruFocus.com

    Eaton Vance Worldwide Health Sciences Fund Buys 2 Stocks

    Health care-focused fund releases 3rd-quarter portfolio Continue reading...

  • PR Newswire

    Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

    "We know that living with type 1 diabetes means dealing with highs and lows in blood sugar, which are worrying and present substantial challenges for young people," said Prof. Dr. Thomas Danne, Director of the Department of General Pediatrics and Endocrinology/Diabetology at the Children's Hospital On the Bult, Hannover Medical School, Germany. The trial, EDITION JUNIOR, is the first randomized, controlled trial comparing Toujeo vs Gla-100 in this group of patients.

  • Morningstar

    Rounding Up Big Pharma Earnings

    Bayer Shows Strength Across Portfolio as Litigation Concerns Continue Bayer BAYRY reported third-quarter results largely in line with our projections. We continue to view the company as undervalued, with the market attributing too much concern to the ongoing glyphosate litigation.

  • Amid hiring shortage, MilliporeSigma draws in workers with ESL classes
    American City Business Journals

    Amid hiring shortage, MilliporeSigma draws in workers with ESL classes

    Over the last three years, MilliporeSigma has boosted job applications and retention at its Danvers site, in part by introducing ESL classes.

  • Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
    Zacks

    Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

    Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

  • Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates
    Zacks

    Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates

    Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

  • Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales
    Zacks

    Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales

    Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.

  • Sanofi Q3 well on track
    PR Newswire

    Sanofi Q3 well on track

    PARIS , Oct. 31, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN)  Q3 2019 Change Change at CER 9M 2019 Change Change at CER IFRS net sales reported €9,499m +1.1% -1.1% €26,518m +4.1% +2.2% IFRS ...

  • Bloomberg

    Sanofi Profit Beats Estimates With New CEO Hudson at Helm

    (Bloomberg) -- Sanofi’s key growth driver, a drug for eczema and asthma, helped the French pharma giant report earnings that beat analysts’ estimates in Paul Hudson’s first quarter as chief executive officer.Earnings excluding some items climbed 4.3% to 1.92 euros a share in the quarter. Analysts predicted earnings of 1.72 euros a share. The company reiterated its forecast of 5% growth for the year.Key InsightsSanofi’s new chief, who took the reins last month, will face questions on the future of the company’s consumer-health and diabetes units, R&D priorities and M&A plans. An experimental cancer combination was stopped in the quarter for efficacy reasons, along with an early-stage treatment for obesity and diabetes, Sanofi said. Hudson is expected to accelerate efforts to revamp the pipeline in the coming months.The hemophilia medicine Eloctate will be in focus after disappointing results pushed the drugmaker in July to curtail sales projections and announce a 1.8 billion-euro ($2 billion) charge.Market PerformanceThe stock rose as much as 1.7% in early Paris trading. The shares have gained about 12% so far this year, compared with a 20% gain in the Bloomberg Europe 500 Pharmaceuticals Index.Get MoreRead more details.See the statement.(Updates with share price in market performance section.)To contact the reporter on this story: James Paton in London at jpaton4@bloomberg.netTo contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, Marthe Fourcade, Frank ConnellyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Sanofi confident for 2019 despite third-quarter sales slip
    Reuters

    Sanofi confident for 2019 despite third-quarter sales slip

    Sanofi expressed confidence for the fourth quarter and confirmed its full-year objectives on Thursday after posting lower third-quarter sales, hit by a fall in revenue at its primary care and vaccines businesses. Shares in Sanofi were down 1.6% at 83.89 euros by 1430 GMT, underperforming a 0.16% drop in the wider market . "Focus remains on the Dec 10 capital markets day," Jefferies analysts wrote in a note to clients, at which the group's newly appointed chief executive Paul Hudson is expected to unveil Sanofi's middle and long term strategy.

  • Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
    Zacks

    Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More

    Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.